Nasdaq

Solésence Reports Record Third Quarter 2026 Financial Results

12-11-2026

Third quarter revenue increases 38% year-over-year to $20.2 million

Third quarter net income of $3.7 million highest in company’s history

Company to host conference call today at 4:00 p.m. CT, 5:00 p.m. ET

ROMEOVILLE, Ill., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the third quarter ended September 30, 2026.

“We’re very pleased that Solésence delivered solid top line growth as well as steady operational and strategic progress in the third quarter, driven by key milestones across our Transform and Transcend framework,” said Kevin Cureton, President and CEO. “Most notably, we reached a major turning point by completing the primary investment and implementation phase of our first pillar, operational excellence. This elevated capacity and efficiency position us to meet robust demand from our brand partners today while seamlessly scaling for tomorrow. Paired with our continued innovation in novel formulations and expanding global presence, Solésence is uniquely positioned to deliver long-term, profitable growth and lead the market in meeting evolving consumer needs.”

Third Quarter 2026 Financial Highlights

Third quarter revenue was $20.2 million, compared to $14.6 million for the same period in 2025.
Gross profit in the third quarter was $7.9 million, compared to $3.5 million for the same period in 2025.
Gross margin in the third quarter was 39.3%, compared to 23.8% for the same period in 2025.
Net income for the third quarter was $3.7 million, compared to a net loss of $1.0 million for the same period in 2025.

"By pairing record revenue and net income with strong margin expansion, we have positioned Solésence for sustained growth," said Laura Riffner, Chief Financial Officer. "The operational and financial improvements achieved throughout 2026 provide a strong foundation as we look ahead to 2027."

Conference Call
Solésence will host its third quarter conference call today at 4:00 p.m. CT, 5:00 p.m. ET, to discuss its financial results and provide a business and financial update. On the call will be Kevin Cureton, President and Chief Executive Officer, and Laura Riffner, Chief Financial Officer.

Webcast Link: https://edge.media-server.com/mmc/p/ym5i5dtt

Dial-In Link: https://register-conf.media-server.com/register/BI29b457cda9bc4600ac796e66eed97ca0

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.

The call may also be accessed through the Company’s investor relations website, at https://ir.solesence.com/. Please join the conference call at least five minutes prior to the start time.

FINANCIAL RESULTS AND NON-GAAP INFORMATION Use of Non-GAAP Financial Information
Solésence believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles (“GAAP”) and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP.

About Solésence, Inc.
Solésence, Inc. (Nasdaq: SLSN), is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com.

Forward-Looking Statements
This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 31, 2026, as amended by Form 10-K/A filed on November 10, 2026. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.

Media Contact:
media@solesence.com

Investor Relations Contact:
investors@solesence.com

SOLESENCE, INC

CONSOLIDATED BALANCE SHEETS
(Unaudited Consolidated Condensed)

	(in thousands except share and per share data)
	September 30,			December 31,
		2026			2025
ASSETS	(Unaudited)			(Unaudited)

Current assets:
Cash	$	1,270		$	1,288
Trade accounts receivable		9,222			7,642
Allowance for credit losses		(858	)		(806	)
Trade accounts receivable, net		8,364			6,836
Inventories, net		11,593			14,879
Prepaid expenses and other current assets		2,030			2,141
Total current assets		23,257			25,144

Equipment and leasehold improvements, net		15,012			14,329
Operating leases, right of use		6,135			6,913
Other assets, net		36			37
Total assets	$	44,440		$	46,423

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Line of credit, accounts receivable, related party		1,029			4,767
Current portion of operating lease obligations		1,409			1,255
Accounts payable		4,528			4,098
Deferred revenue		2,147			930
Accrued expenses		4,337			2,879
Total current liabilities		13,450			13,929

Long-term portion of operating lease obligations		6,736			7,798
Long-term portion of line of credit, inventory, related party		6,300			9,500
Long-term portion of debt, related parties		1,000			1,000
Asset retirement obligations		203			194
Total long-term liabilities		14,239			18,492

Stockholders' equity:
Preferred stock, $.01 par value, 24,088 shares authorized and
no shares issued and outstanding		-			-
Common stock, $.01 par value, 95,000,000 shares authorized;
70,632,445 and 70,614,045 shares issued and outstanding on March 31, 2026
and December 31, 2025, respectively		706			706
Additional paid-in capital		115,837			115,566
Accumulated deficit		(99,792	)		(102,270	)
Total stockholders' equity		16,751			14,002
Total liabilities and shareholders' equity	$	44,440		$	46,423

SOLESENCE, INC

CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)

	Three months ended						Nine months ended
	September 30,						September 30,
		2026			2025			2026		2025
Revenue:
Product revenue	$	19,978		$	14,533		$	48,184	$	49,369
Other revenue		185			64			269		212
Net revenue		20,163			14,597			48,453		49,581

Cost of revenue		12,235			11,123			32,708		36,043
Gross profit		7,928			3,474			15,745		13,538

Operating expense:
Research and development expense		1,082			1,082			3,071		3,055
Selling, general and administrative expense		2,810			3,069			9,287		8,188
Net (loss) income from operations		4,036			(677	)		3,387		2,295
Interest income		-			-			-		-
Interest expense		258			339			801		603
Other nonoperating income		111			-			111		1,234
Net (loss) income before provision for income taxes		3,889			(1,016	)		2,697		2,926
Provision for income taxes		219			-			219		390
Net (loss) income	$	3,670		$	(1,016	)	$	2,478	$	2,536


Net (loss) income per share-basic	$	0.05		$	(0.01	)	$	0.04	$	0.04

Weighted average number of common shares outstanding - basic		70,647,045			70,500,925			70,636,660		70,269,539

Net (loss) income per share-diluted	$	0.05		$	(0.01	)	$	0.03	$	0.03

Weighted average number of common shares outstanding - diluted		71,483,887			70,500,925			71,551,693		72,745,662


SOLESENCE, INC

CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)

	Three months ended						Nine months ended
	September 30,						September 30,
		2026			2025			2026		2025
Revenue:
Product revenue	$	19,978		$	14,533		$	48,184	$	49,369
Other revenue		185			64			269		212
Net revenue		20,163			14,597			48,453		49,581

Cost of revenue detail:
Depreciation		301			217			911		649
Non-Cash equity compensation		18			19			60		73
Other costs of revenue		11,916			10,887			31,737		35,321
Cost of revenue		12,235			11,123			32,708		36,043
Gross profit		7,928			3,474			15,745		13,538

Operating expense:
Research and development expense detail:
Depreciation		(1	)		2			9		9
Non-Cash equity compensation		8			27			43		82
Other research and development expense		1,075			1,053			3,019		2,964
Research and development expense		1,082			1,082			3,071		3,055

Selling, general and administrative expense detail:
Depreciation and amortization		7			6			23		17
Non-Cash equity compensation		47			61			133		199
Other selling, general and administrative expense		2,756			3,002			9,131		7,972
Selling, general and administrative expense		2,810			3,069			9,287		8,188
Net (loss) income from operations		4,036			(677	)		3,387		2,295
Interest income
Interest expense		258			339			801		603
Other nonoperating income		111			-			111		1,234
Net (loss) income before provision for income taxes		3,889			(1,016	)		2,697		2,926
Provision for income taxes		219			-			219		390
Net (loss) income	$	3,670		$	(1,016	)	$	2,478	$	2,536

Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):
Addback Interest, net		258			339			801		603
Addback Depreciation/Amortization		307			225			943		675
Addback Non-Cash Equity Compensation		73			107			236		354
Subtract Non-Cash Other Income		-			-			-		-

Adjusted EBITDA	$	4,308		$	(345	)	$	4,458	$	4,168

Latest Health & Supplement Reviews